Tickers

1. Composite Trajectory Verdict

Given MCK's high-volume, low-margin pharmaceutical distribution model, the income statement and cash flow statement carry the most weight for assessing operational performance, while the balance sheet is critical for evaluating the sustainability of its capital return program and litigation obligations.

Composite Trajectory: Mixed

Operating results show strong top-line and bottom-line growth: revenue rose 12% to $403.4B, operating income increased 40% to $6.2B, and diluted EPS jumped 49% to $38.38 in FY2026 versus FY2025 (10-K 2026-03-31, Consolidated Statements of Operations). However, gross margin has compressed for three consecutive years (3.61% in FY2026 vs 3.71% in FY2025 vs 4.15% in FY2024), working capital deteriorated to -$9.8B from -$6.2B, total debt rose to $6.5B while cash fell to $4.0B, and the debt-to-capital ratio climbed to 128% from 125% (10-K 2026-03-31, MD&A Selected Measures of Liquidity). The opioid litigation liability remains at $5.7B with $601M due within 12 months (10-K 2026-03-31, MD&A Material Cash Requirements). These opposing trends — robust earnings growth against margin erosion, leverage increase, and persistent contingent liabilities — produce a mixed overall trajectory.

2. Red Flags

• Gross margin compression for three straight years: 3.61% (FY2026) → 3.71% (FY2025) → 4.15% (FY2024) despite revenue growing 12% and 16% respectively (10-K 2026-03-31, Consolidated Statements of Operations; 10-K 2026-03-31, MD&A Overview of Consolidated Results).
• Working capital deterioration: Negative working capital widened to -$9,807M at March 31, 2026 from -$6,206M at March 31, 2025 (10-K 2026-03-31, MD&A Selected Measures of Liquidity).
• Leverage rising while cash declines: Total debt increased to $6,526M from $5,654M; cash and equivalents fell to $3,975M from $5,691M; debt-to-capital ratio rose to 128.0% from 125.3% (10-K 2026-03-31, Consolidated Balance Sheets; 10-K 2026-03-31, MD&A Selected Measures of Liquidity).
• Share repurchases exceed operating cash flow: $4.8B of repurchases in FY2026 vs $6.2B operating cash flow, with net cash used in financing activities of $4.6B (10-K 2026-03-31, Consolidated Statements of Cash Flows).
• Large opioid litigation liability: $5.7B accrued at March 31, 2026, with $601M estimated payable within 12 months (10-K 2026-03-31, MD&A Material Cash Requirements).
• Redeemable noncontrolling interests with put rights: $943M recognized in FY2026 for Core Ventures ($700M) and PRISM Vision ($25M), with $122M redemption value adjustment charged to net income attributable to noncontrolling interests (10-K 2026-03-31, Financial Note 7).
• Unrecognized tax benefits growing: $1.6B at March 31, 2026 vs $1.5B at March 31, 2025, with IRS proposed adjustments of $600-700M for FY2018-2019 (10-K 2026-03-31, Financial Note 6).
• Restructuring charges recurring: $245M in FY2026, $344M in FY2025, $115M in FY2024, with new programs approved each year (10-K 2026-03-31, Financial Note 3).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Revenue grew 12% to $403.4B in FY2026 from $359.1B in FY2025, driven by North American Pharmaceutical (+11% to $336.7B) and Oncology & Multispecialty (+31% to $48.4B) (10-K 2026-03-31, Consolidated Statements of Operations; MD&A Overview of Segment Results). Operating income surged 40% to $6.2B, and net income attributable to McKesson rose 45% to $4.8B, with diluted EPS up 49% to $38.38 (10-K 2026-03-31, Consolidated Statements of Operations). However, gross margin contracted 10 basis points to 3.61% from 3.71%, marking the third consecutive year of decline (4.15% in FY2024) (10-K 2026-03-31, MD&A Overview of Consolidated Results). Segment operating margins improved in Oncology & Multispecialty (2.37% vs 2.08%), Prescription Technology Solutions (17.98% vs 16.78%), and Medical-Surgical Solutions (8.15% vs 6.85%), but North American Pharmaceutical margin only improved to 1.09% from 0.97% (10-K 2026-03-31, MD&A Overview of Segment Results). The EPS benefit was amplified by a 3% reduction in weighted-average diluted shares to 124.1M from 128.1M due to repurchases (10-K 2026-03-31, Consolidated Statements of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Operating cash flow was essentially flat at $6.2B in FY2026 versus $6.1B in FY2025, up from $4.3B in FY2024 (10-K 2026-03-31, Consolidated Statements of Cash Flows). Capital expenditures remained steady at $745M (PPE $436M + software $309M) in FY2026 versus $859M in FY2025 (10-K 2026-03-31, Consolidated Statements of Cash Flows). Free cash flow (operating cash flow less capex) improved to approximately $5.4B from $5.2B. However, investing cash outflows jumped to $3.4B in FY2026 from $733M in FY2025, driven by $3.4B of acquisition spending (Core Ventures $2.5B, PRISM Vision $875M) (10-K 2026-03-31, Consolidated Statements of Cash Flows; MD&A Investing Activities). Financing outflows totaled $4.6B, including $4.8B of share repurchases and $381M of dividends, funded partly by $2.0B of new long-term debt issuance (10-K 2026-03-31, Consolidated Statements of Cash Flows; MD&A Financing Activities). Cash and equivalents declined to $4.0B from $6.0B year-over-year (10-K 2026-03-31, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Total assets grew to $82.3B from $75.1B, primarily from goodwill ($11.3B vs $10.0B) and intangible assets ($4.1B vs $1.5B) due to acquisitions (10-K 2026-03-31, Consolidated Balance Sheets). Total debt increased to $6.5B from $5.7B, with the current portion rising to $1.3B from $1.2B (10-K 2026-03-31, Consolidated Balance Sheets; Financial Note 11). Cash fell to $4.0B from $5.7B. Working capital worsened to -$9.8B from -$6.2B, driven by higher drafts and accounts payable ($60.0B vs $55.3B) and lower cash (10-K 2026-03-31, MD&A Selected Measures of Liquidity). The debt-to-capital ratio rose to 128.0% from 125.3% (10-K 2026-03-31, MD&A Selected Measures of Liquidity). Long-term litigation liabilities (primarily opioid) decreased modestly to $5.1B from $5.6B but remain substantial (10-K 2026-03-31, Consolidated Balance Sheets). Redeemable noncontrolling interests of $943M appeared on the balance sheet for the first time (10-K 2026-03-31, Consolidated Balance Sheets). Stockholders' deficit deepened to -$2.2B from -$2.1B despite $4.8B net income, due to $4.8B of share repurchases and $393M of dividends (10-K 2026-03-31, Consolidated Statements of Stockholders' Deficit).

6. Data Gaps

• Quarterly revenue, gross profit, operating income, and EPS for Q1-Q4 FY2026 and FY2025 to assess intra-year trends and seasonality (10-Qs for periods ending 2025-06-30, 2025-09-30, 2025-12-31, 2026-03-31 would provide this)
• Quarterly operating cash flow, capex, and free cash flow for the same periods
• Quarterly working capital components (receivables, inventory, payables days) to understand the working capital deterioration trajectory
• Segment-level quarterly revenue and operating profit to track Oncology & Multispecialty integration progress
• FY2024 gross margin calculation (only FY2026 and FY2025 explicitly stated in MD&A; FY2024 derived from statements)